L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review.
作者： Youtao Xu , Wenjie Xia , Lin Xu , Feng Jiang , Jie Wang
DOI: 10.3978/J.ISSN.2072-1439.2014.08.17
关键词: Oncology 、 Immunotherapy 、 Maintenance therapy 、 Lung cancer 、 non-small cell lung cancer (NSCLC) 、 Pathology 、 Peptide vaccine 、 Chemotherapy 、 Clinical trial 、 Stage (cooking) 、 Internal medicine 、 Medicine
摘要: Lung cancer is one of the most prevalent malignancies worldwide and leading cause cancer-related death. Most cases are non-small cell lung (NSCLC). The median overall survival patients with advanced stage undergoing current standard chemotherapy approximately 10 months. addition new compounds, including targeted agents, to first-line cytotoxic doublets, which administered concurrently and/or as maintenance therapy in who have not experienced disease progression after treatment, has shown potential improving efficacy disease. L-BLP25 a mucin 1 (MUC1) antigen-specific immunotherapy induces T-cell response MUC1 both preclinical MUC1-transgenic mouse model patients. This review aimed at introducing mechanism by targets MUC1, summarizing achievements gained completed clinical trials treatment unresectable III/IV NSCLC, discussing research trends.
amegroups.com参考文章(43)
V Apostolopoulos, G A Pietersz, I F McKenzie, MUC1 and breast cancer. Current Opinion in Molecular Therapeutics. ,vol. 1, pp. 98- 103 ,(1999)
Olivera J. Finn, Joyce Taylor-Papadimitriou, Robert C. Bast, Cinda M. Boyer, Katharine M. Bendt, Keith R. Jerome, Ian F. C. McKenzie, Donna L. Barnd, Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Research. ,vol. 51, pp. 2908- 2916 ,(1991)
Wanqing Chen, Siwei Zhang, Xiaonong Zou, Evaluation on the incidence, mortality and tendency of lung cancer in China. Thoracic Cancer. ,vol. 1, pp. 35- 40 ,(2010) , 10.1111/J.1759-7714.2010.00011.X
Olivera J. Finn, Nieves Domenech, Keith R. Jerome, Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. Journal of Immunology. ,vol. 151, pp. 1654- 1662 ,(1993)
C G Ioannides, O J Finn, B Fisk, T Irimura, J T Wharton, K R Jerome, Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. Journal of Immunology. ,vol. 151, pp. 3693- 3703 ,(1993)
François Ghiringhelli, Cedric Menard, Pierre Emmanuel Puig, Sylvain Ladoire, Stephan Roux, François Martin, Eric Solary, Axel Le Cesne, Laurence Zitvogel, Bruno Chauffert, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunology, Immunotherapy. ,vol. 56, pp. 641- 648 ,(2007) , 10.1007/S00262-006-0225-8
Jacques Ferlay, Hai-Rim Shin, Freddie Bray, David Forman, Colin Mathers, Donald Maxwell Parkin, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. ,vol. 127, pp. 2893- 2917 ,(2010) , 10.1002/IJC.25516
Chiao-Jung Kao, Gregory T. Wurz, Andreas Schroder, Michael Wolf, Michael W. DeGregorio, Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy OncoImmunology. ,vol. 2, ,(2013) , 10.4161/ONCI.26285
S Bafna, S Kaur, S K Batra, Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene. ,vol. 29, pp. 2893- 2904 ,(2010) , 10.1038/ONC.2010.87
Charles Butts, Andrew Maksymiuk, Glenwood Goss, Denis Soulières, Ernie Marshall, Yvon Cormier, Peter M. Ellis, Allan Price, Ravinder Sawhney, Frank Beier, Martin Falk, Nevin Murray, Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial Journal of Cancer Research and Clinical Oncology. ,vol. 137, pp. 1337- 1342 ,(2011) , 10.1007/S00432-011-1003-3